Context: Prior testing of Del-Immune V® has indicated effectiveness for immune system support; however, mechanisms of action and optimal doses have not yet been researched.
INTRODUCTION
Among a large number of presently known therapeutic products that utilize lactobacilli, cell wall peptidoglycan is enjoying growing popularity as an immunomodulator that contains, among other things, fragments of DNA and cell peptidoglycan of the strain The biochemical structure of Del-Immune V and preliminary experimental and clinical data indicate that Del-Immune V may be highly effective in infectious diseases of viral (flu, hepatitis C), bacterial (bronchitis), and fungal etiology, allergies of all severity levels, asthma, chronic fatigue, and fibromyalgia. [1] [2] [3] [4] [5] [6] The mechanism of such a wide scope of biological activity of the formulation is still unclear. The goal of our research, therefore, was to study the mechanisms of the immunomodulating effects of Del-Immune V and to describe its dose-dependent effects on production of immunoregulatory cytokines in vivo and in vitro.
The last 5 years have been marked by increasingly active study of the mechanisms of the immunobiological effects of probiotics and bacterial medications. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] As a result, bacterial medications such as liastenum (blasten), deodan, licopid, prodigiosanum, salmosanum, Fragments of probiotic bacterial DNA are interesting because of their capacity to stimulate production of cytotoxic lymphocytes and NKC, activate the complement system, heighten cytostatic and cytotoxic activity of macrophages, and regulate production of immunoregulatory cytokines. 11, 15 Owing to the ТТТСGТТТ DNA pattern of the strain, Lactobacillus rhamnosus GG was found to be a factor preconditioning immunobiological activity of the probiotic producer. 16 Thus, CpG DNA are identified with the help of TLR9
and TLR10 expressed in the intercellular (endosomes) cell compartments. CpG DNA identification with TLR9 and TLR10 results in activation of neutrophils and cytokine production.
27-29

MATERIALS AND METHODS
The study examined the dose-dependent effect of Del-Immune V on production of immunoregulatory cytokines in nondescript mice with body mass of 14-16g. One hundred forty animals were selected on the basis of the analogue principle, and were divided into 7 The optimal dose of Del-Immune V was also tested via in vitro induction of immunoregulatory cytokines in splenocytes and PEM (1х10 7 cell/ml) of treated and intact mice by culturing cells with the formulation in final concentrations of 5, 50, and 500 µg/ml.
Interferonogenous activity of the tested formulations was assessed in comparison with
Bifidim 50 µg/ml and standard inductors (IFN-α; Newcastle Disease Virus, NDV-10 TCD 50 /cell; IFN-γ; phytohemagglutinin, PHA-20 µg/ml; Difco; TNF, LPS E. Coli 0111-4 µg/ml-Sigma USA). Levels of cytokine production (IFN and TNF) were determined 6, 24, and 48 hours after incubation of the cell with the formulations.
Biological activity of TNF was assessed by cytotoxicity in the passaged culture of murine fibroblasts L-929. 30 The result was recorded on a multiscanner (Dynatech, Switzerland) with a wavelength of 540 nm. The cytotoxicity index was calculated using the formula CI = К-О/Кх100%, where К and О represent optical density values for the cell in the by Student-Fisher t-test. Differences of P < .05 were considered to be significant.
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RESULTS
Daily oral administration of Del-Immune V or Bifidim to Groups I-III in the course of 5 days in doses of 5, 50, or 500 µg/mouse resulted in a marked increase in IFN levels in blood serum (see Figure 1 ). The optimal interferonogenous dose was found to be 50 µg/mouse (Group II). After 24 hours of observation, circulating IFN levels in Group II reached 4.5 log 2 U/ml (P > .05). After repeated administrations, levels reached 5.5±0.7 log 2 U/ml (P > .05), in comparison with 2.0±0.7 log 2 U/ml in the control group (Group V). Further administration of Del-Immune V in a dose of 50 µg/mouse on day 3 allowed for maintenance of the 5.5±0.5 log 2 U/ml level. Administration of the formulation on days 4 and 5 resulted in nonsignificant decreases in circulating IFN levels. When Del-Immune V was administered in doses of 5 and 500 µg/mouse (Groups II and III), findings were similar, although maximum interferon levels were not as high.
Insert Figure 1 about here.
One-time oral administration of Del-Immune V or Bifidim to mice in a dose of 50 µg/ml resulted in increased circulating IFN level 8 hours after administration. The highest serum IFN level was reported 24 hours after administration, while levels in control group animals remained unchanged (see Table 1 ).
Insert Table 1 (including T-helpers stimulating maturation of NK-cells as well as some subpopulations of Blymphocytes) is impossible. [37] [38] [39] [40] [41] [42] IFN-γ also participates in the immune response of macrophage cells, inducing production of TNF and IL-1 43 and modulating their functions. 44 Therefore, the level of TNF, a pleiotropic cytokine produced by primed monocytes and macrophages, lymphocytes, and NKC, was assessed in murine serum (see Figure 4) . [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] Oral administration of Del-Immune V or Bifidim in doses of 5, 50, or 500 µg/mouse resulted in endogenous TNF production.
After administration of Del-Immune V or Bifidim in a dose of 50 µg/ml, serum TNF was 0.6 ng/ml (P < .05) and 0.8 ng/ml (P < .05), respectively, while in the control group it did not exceed 0.3 ng/ml. Maximum production of this cytokine was reported 8 hours after administration of these formulations.
Insert Figure 4 about here.
Del-Immune V administered in a dose of 5 µg/mouse resulted in an insignificant increase in circulating TNF concentration to 0.4 ng/ml (P > .05), in comparison with 0.3 ng/ml in the control group. It should be noted that oral administration of Del-Immune V in doses of 50
and 500 µg/ml resulted in practically equal circulating TNF indices (0.6 ng/ml and 0.7 ng/ml, respectively). This TNF production in vivo calls for further studies since TNF mobilizes leukocytes, terminates inflammatory processes, and plays an important role in the effector and regulatory networks of body immune response. Enhanced TNF production leads to activation of neutrophils, macrophages, and lymphocytes, thus strengthening anti-infection immunity. B-lymphocytes. It should be noted that circulating TNF was quickly eliminated from the body.
In vitro trials showed that adding Del-Immune V or Bifidim in concentrations of 5, 50, or 100 µg/ml to macrophages of experimental and intact mice resulted in TNF production peaking 8 hours after adding these formulations ( Figure 5 ). TNF production potential of PEM was dose-dependent. The optimal in vitro concentration of Del-Immune V and Bifidim was 50 µg/ml.
Insert 
